The global market for drugs treating Central Nervous System (CNS) disorders has grown rapidly in recent years to reach US$55.5 billion in 2005, a year-on-year increase of 6.6%.
Between 2003 and 2005, global CNS sales increased by 19% and accounted for 9.2% of total global pharmaceutical sales in 2005. Annual global CNS sales growth slowed from 11.5% in 2004 to 6.6% in 2005 as a result of generic competition for leading anti-depressant and epilepsy therapies.
CNS Market Trends, 2007-2010 - Key market forecasts and growth opportunities provides an in-depth analysis of the growing market for pharmaceutical treatments for central nervous system (CNS) disorders.
This comprehensive report delivers market forecasts and overviews to help inform you in your pharmaceutical business decision-making.
Particular attention is drawn to the following drug classes; Epilepsy, Alzheimer's Disease, Migraines, ADHD, Parkinson's Disease.
Key findings from the report include:
The global CNS market is forecast to expand to US$63.9 billion in 2010 but growth will be limited by mature markets in depression and epilepsy and continued patent expiries for major products.
Of the top 20 products by global CNS sales in 2005, 13 generated annual sales in excess of US$1 billion.
5 of the top 10 CNS companies AstraZeneca, Forest, GSK, Sanofi-Aventis and Wyeth are forecast to grow their CNS sales over the next five years. J&J, Novartis and Abbott are forecast to suffer declining CNS sales over the next five years.
A total of 15 pharmaceutical companies were identified as having generated CNS sales in excess of US$1 billion in 2005.
Topamax was the leading epilepsy drug in 2005 with sales of US$1.7 billion. Other blockbuster epilepsy drugs include the second generation anti-convulsant, Lamictal and traditional anti-convulsant, Depakote.
The global market for CNS-related pharmaceuticals was dominated by the anti-depressant drug class with a market share of more than 30%
This report provides key information needed in your business including:
Sales forecast for top ten companies providing CNS treatment medicines.
Analysis of leading CNS products likely to loose patent protection in the next ten years.
Sales forecasts to 2010 for the top ten CNS medicines and forecasts by drug class.
Overview of disease incidence, areas of growth and breakdown of disease burden and mortality.
Breakdown of the major market trends and business opportunities.
In-depth coverage of the following companies' CNS market presence: Abbott, AstraZeneca, Eli Lilly, Forest, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, Sanofi-Aventis, Wyeth.
Use This Report To:
1. Benchmark your company's portfolio against market trends and forecasts to plan better for greater profitability.
2. Spot areas of pharmaceutical market growth and good opportunities for delivering successful sales growth.
3. Support your internal planning processes by using an external perspective founded on detailed analysis and transparent market forecasts.
The 135 page publication contains 53 Figures and 54 Tables to help you make sense of the wealth of data. This report will be of particular use to those involved in:
- pharmaceutical company corporate planning,
- portfolio management, and,
- market and sales forecasting.
The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. Chapter 6 outlines future CNS market trends and major growth opportunities. The data and analysis contained within the report are comprehensive, consistent and up-to-date and thus provide a single-point of reference for understanding CNS market trends.
(0 items)
